CN102414313B - 多基因载体编码的重组病毒样颗粒 - Google Patents

多基因载体编码的重组病毒样颗粒 Download PDF

Info

Publication number
CN102414313B
CN102414313B CN201080018892.8A CN201080018892A CN102414313B CN 102414313 B CN102414313 B CN 102414313B CN 201080018892 A CN201080018892 A CN 201080018892A CN 102414313 B CN102414313 B CN 102414313B
Authority
CN
China
Prior art keywords
virus
particles
different
epitopes
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080018892.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102414313A (zh
Inventor
C.约翰
C.绍布
S.韦尔尼茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Redvax GmbH
Pfizer Inc
Original Assignee
Redbiotec AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redbiotec AG filed Critical Redbiotec AG
Publication of CN102414313A publication Critical patent/CN102414313A/zh
Application granted granted Critical
Publication of CN102414313B publication Critical patent/CN102414313B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/866—Baculoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201080018892.8A 2009-05-01 2010-04-30 多基因载体编码的重组病毒样颗粒 Expired - Fee Related CN102414313B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09159287.3 2009-05-01
EP09159287 2009-05-01
PCT/EP2010/055943 WO2010125201A1 (en) 2009-05-01 2010-04-30 Recombinant virus-like particles encoded by multi-gene vector

Publications (2)

Publication Number Publication Date
CN102414313A CN102414313A (zh) 2012-04-11
CN102414313B true CN102414313B (zh) 2014-04-02

Family

ID=42544386

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080018892.8A Expired - Fee Related CN102414313B (zh) 2009-05-01 2010-04-30 多基因载体编码的重组病毒样颗粒

Country Status (12)

Country Link
US (3) US20120064115A1 (enExample)
EP (2) EP2424980A1 (enExample)
JP (2) JP2012525133A (enExample)
KR (1) KR20120018783A (enExample)
CN (1) CN102414313B (enExample)
AU (2) AU2010243489A1 (enExample)
CA (1) CA2760524C (enExample)
IL (2) IL216005A (enExample)
NZ (1) NZ595710A (enExample)
SG (2) SG175781A1 (enExample)
WO (1) WO2010125201A1 (enExample)
ZA (1) ZA201108036B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010243489A1 (en) * 2009-05-01 2011-12-22 Redbiotec Ag Recombinant virus-like particles encoded by multi-gene vector
US9284533B2 (en) 2011-06-24 2016-03-15 Flugen, Inc. Influenza virus mutants and uses therefor
US20150359879A1 (en) * 2012-10-30 2015-12-17 Redvax Gmbh Recombinant particle based vaccines against human cytomegalovirus infection
CN103421845B (zh) * 2013-03-01 2015-10-21 湖州市农业科学研究院 重组质粒pFastdual-polh-da26-Asp、家蚕杆状重组病毒及利用该病毒生产L-天冬酰胺酶Ⅱ的方法
CN107106689A (zh) 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
WO2017023724A1 (en) * 2015-07-31 2017-02-09 Voyager Therapeutics, Inc. Compositions and methods for the treatment of aadc deficiency
US9996448B2 (en) * 2016-02-25 2018-06-12 Red Hat Israel Ltd Breakpoint insertion into kernel pages
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11058765B2 (en) * 2016-03-14 2021-07-13 Redbiotec Ag Means and methods for treating HSV
US10417116B2 (en) * 2016-07-28 2019-09-17 International Business Machines Corporation System, method, and apparatus for crowd-sourced gathering of application execution events for automatic application testing and replay
JP2019531787A (ja) 2016-08-30 2019-11-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物医学的ターゲティング及びデリバリーの方法並びにそれを実行するための装置及びシステム
WO2018176075A1 (en) * 2017-03-27 2018-10-04 The University Of Queensland Chimeric insect-specific flaviviruses
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CN111132626B (zh) 2017-07-17 2024-01-30 沃雅戈治疗公司 轨迹阵列引导系统
MX2020012077A (es) 2018-05-15 2021-03-09 Voyager Therapeutics Inc Composiciones y metodos para el tratamiento de la enfermedad de parkinson.
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN109731100A (zh) * 2019-02-15 2019-05-10 华南农业大学 基于MultiBac杆状病毒表达系统的禽流感疫苗及制备与应用
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
KR102508574B1 (ko) * 2021-01-22 2023-03-10 주식회사 헬스파크 톡소포자충 단백질 및 인플루엔자 바이러스 단백질을 포함하는 바이러스 유사 입자 및 이를 이용한 진단 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092827A2 (en) * 2001-05-17 2002-11-21 Universiteit Utrecht Corona-virus-like particles comprising functionally deleted genomes
WO2004092387A1 (en) * 2003-04-17 2004-10-28 Hepgenics Pty Ltd Viral vectors expressing fusion of viral large envelope protein and protein of interest
WO2005085456A1 (en) * 2004-03-09 2005-09-15 Eidgenoessische Technische Hochschule Zurich New expression tools for multiprotein applications

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908613B2 (en) 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
EP1294892B1 (en) * 2000-06-23 2007-10-17 Wyeth Holdings Corporation Assembly of wild-type and chimeric influenza virus-like particles (vlps)
US7556957B2 (en) 2001-05-17 2009-07-07 Stichting Voor De Technische Wetenschappen Coronavirus-like particles comprising functionally deleted genomes
US20050186575A1 (en) 2001-05-17 2005-08-25 Rottier Petrus J.M. Corona-virus-like particles comprising functionally deleted genomes
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
BRPI0617486A2 (pt) * 2005-10-18 2011-07-26 Novavax Inc vacina que compreende partÍculas similares a vÍrus da gripe funcionais (vlp) e uso de uma vlp de gripe
EP1783228A1 (en) 2005-11-08 2007-05-09 ETH Zürich Recombinant expression of multiprotein complexes using polygenes
WO2007130330A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Polyvalent influenza virus-like particle (vlp) compositions
WO2008094197A2 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
WO2009012487A2 (en) * 2007-07-19 2009-01-22 Novavax, Inc. Chimeric varicella zoster virus-virus like particles
AU2010243489A1 (en) * 2009-05-01 2011-12-22 Redbiotec Ag Recombinant virus-like particles encoded by multi-gene vector

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092827A2 (en) * 2001-05-17 2002-11-21 Universiteit Utrecht Corona-virus-like particles comprising functionally deleted genomes
CN1620500A (zh) * 2001-05-17 2005-05-25 乌得勒支大学 包含功能性缺失的基因组的冠状病毒样颗粒
WO2004092387A1 (en) * 2003-04-17 2004-10-28 Hepgenics Pty Ltd Viral vectors expressing fusion of viral large envelope protein and protein of interest
CN1791675A (zh) * 2003-04-17 2006-06-21 赫普吉尼克斯股份有限公司 表达病毒大包膜蛋白和目的蛋白融合体的病毒载体
WO2005085456A1 (en) * 2004-03-09 2005-09-15 Eidgenoessische Technische Hochschule Zurich New expression tools for multiprotein applications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Enhanced immunogenicity of modified hepatitis B virus core particle fused with multiepitopes of foot-and-mouth disease virus;ZHANG YL ET AL;《SCANDINAVIAN JOURNAL OF IMMUNOLOGY》;20070401;第65卷(第4期);320-328 *

Also Published As

Publication number Publication date
CA2760524C (en) 2017-09-12
US20150004690A1 (en) 2015-01-01
EP2952581A1 (en) 2015-12-09
IL216005A (en) 2015-08-31
JP2016104015A (ja) 2016-06-09
CN102414313A (zh) 2012-04-11
SG10201603033QA (en) 2016-05-30
WO2010125201A1 (en) 2010-11-04
EP2424980A1 (en) 2012-03-07
NZ595710A (en) 2013-10-25
US20120064115A1 (en) 2012-03-15
IL216005A0 (en) 2012-01-31
US20160194662A1 (en) 2016-07-07
JP2012525133A (ja) 2012-10-22
ZA201108036B (en) 2012-08-29
SG175781A1 (en) 2011-12-29
KR20120018783A (ko) 2012-03-05
CA2760524A1 (en) 2010-11-04
AU2010243489A1 (en) 2011-12-22
AU2014203512A1 (en) 2014-07-17
AU2014203512B2 (en) 2016-07-14
US9309536B2 (en) 2016-04-12
IL240043A0 (en) 2015-08-31

Similar Documents

Publication Publication Date Title
CN102414313B (zh) 多基因载体编码的重组病毒样颗粒
JP5008244B2 (ja) 野性型およびキメラのインフルエンザウイルス様粒子（ｖｌｐ）のアセンブリー
AU2022246465A1 (en) Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
CN106460010A (zh) 治疗cmv之手段及方法
CN106232813A (zh) 预防减蛋综合征(eds)的疫苗
EP3265121B1 (en) Marker system, in particular for baculovirus-expressed subunit antigens
JP2019512261A (ja) アデノウイルスコートタンパク質由来送達賦形剤
Sari‐Ak et al. VLP‐factory™ and ADDomer©: self‐assembling virus‐like particle (VLP) technologies for multiple protein and peptide epitope display
WO2021194992A1 (en) Recombinant viruses, insect cells and their uses in viral detection and vaccination
HK1166347A (en) Recombinant virus-like particles encoded by multi-gene vector
HK1166347B (en) Recombinant virus-like particles encoded by multi-gene vector
Behzadian et al. Baculoviral Co-Expression of HA, NA and M1 Proteins of Highly Pathogenic H5N1 Influenza Virus in Insect Cells.
CN114213509B (zh) 基于SARS-CoV-2的S蛋白的疫苗及其用途
CN112458118A (zh) 新流法腺四联病毒样颗粒及其制备方法和应用
CN102643335B (zh) 重组轮状病毒vp6载体蛋白及其制备
ZA200204987B (en) Necleic acid vaccination.
KR20230156945A (ko) 백신 조성물 및 이의 사용 방법
CN115785281B (zh) 含有狂犬病病毒g蛋白的融合蛋白的制备方法及应用
WO2011099541A1 (ja) 組換えウイルスの製造方法
CN102023213B (zh) 一种检测流感病毒抗体的荧光微量细胞凝集方法
CN120718119A (zh) 基于结构设计的稳定于融合前构象的rsv-f蛋白突变体
KR20240125806A (ko) 배큘로바이러스 다각체 단백질의 특정 영역을 이용한 목적 단백질의 나노입자화 방법 및 나노입자화된 목적 단백질의 스크리닝 방법
JP2002034559A (ja) 遺伝子発現単位

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1166347

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1166347

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20151217

Address after: American New York

Patentee after: PFIZER Inc.

Address before: Swiss Shi Lilun

Patentee before: Redbiotec AG

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160321

Address after: American New York

Patentee after: PFIZER Inc.

Address before: Swiss Shi Lilun

Patentee before: Redvax GmbH

Effective date of registration: 20160321

Address after: Swiss Shi Lilun

Patentee after: Redvax GmbH

Address before: Swiss Shi Lilun

Patentee before: Redbiotec AG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140402

Termination date: 20180430

CF01 Termination of patent right due to non-payment of annual fee